MAXONA Pharmaceuticals today announced the United States Patents and Trademark Office (USPTO) has issued Patent No. 12,226,421 for MAX-001, the company's first to market product which is a non-opioid, non-NSAID oral therapy for the treatment of acute and chronic pain. With the issuance of this patent, Maxona Pharmaceuticals now holds a total of five Method of Use and Composition of Matter patents that cover research and uses of nefopam, the active ingredient in MAX-001.

"As a company, one of our priorities has been to develop a strong intellectual property position for MAX-001," said Shawn Fatholahi, president and CEO of Maxona Pharmaceuticals, and the named inventor on the patents. "The addition of this new patent further strengthens our intellectual property portfolio. It also underscores our commitment to fully exploring and leveraging the potential of MAX-001 for its initial indications to treat acute and chronic pain as well as other indications in the future. As we continue to advance our development program for MAX-001, we will seek additional patents related to specific areas of use and optimal formulation of the product by leveraging the company's formulation technology and expertise."

Over the past few years, Maxona Pharmaceuticals has built a world-class management team that has unique experience in all aspects of drug development and commercialization to capitalize on opportunities to bring new therapies such as MAX-001 to the U.S. market. After completion of an extensive formulation optimization process and comprehensive IND-enabling pre-clinical studies, Maxona Pharmaceuticals completed the MAX-001 Phase 1 clinical program earlier this year. The compound will enter Phase 2 clinical trials later this year.

MAX-001 is an optimized formulation of nefopam hydrochloride which is a non-opioid, non-NSAID solid oral therapy being developed as a New Molecular Entity (NME) intended for the treatment of acute and chronic pain in the United States. MAX-001 is designed specifically to deliver both a rapid onset and extended duration of analgesia exerting its effect primarily through a novel mechanism of action as a triple neurotransmitter re-uptake inhibitor with the order of strength being significantly greater for norepinephrine than serotonin, and dopamine respectively (N > S > D). When approved for use, MAX-001 will be the only triple monoamine re-uptake inhibitor with an indication for the treatment of acute pain in the United States.

MAXONA Pharmaceuticals, headquartered in Malvern, PA, is a privately held clinical-stage pharmaceutical company committed to developing the next generation of therapies to help patients maximize life. The company is distinguished by its strong and diversified leadership team with expertise in neuroscience, drug development, drug formulation and delivery technology, clinical trial design and pharmacology to develop patient-centric therapies that are safe, efficacious, clinically proven and trusted by physicians and their patients. The company's initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.

Source: prnewswire.com

Report Abuse